Food and Drug Administration

Food and Drug Administration
Student’s Name
(Institution)

Food and Drug Administration
The systems set in place to implement food and drug policies and regulations have severe limitations and require a complete overhaul. According to Kim & Prasad (2015), the panel officiating all process within the Food and Drug Administration has been reported to have ties with the companies that produce the various foods and drugs consumed in the country. They are either part of the industries as employees or consultants. In this case, biases and overlooking on some of the significant aspects that determine the safety of foods and drugs have become common within the FDA. Frank et al., (2014) argue that some of the decisions passed by the FDA committee lack adequate backing with the knowledge in the food and drug fields of study. In April 2013, the FDA adopted regulations that categorised feces as a drug forcing doctors intending to use the implants to respond to an investigations new drug application form before they could move ahead with administering the medication (Kim & Prasad, 2015). FDA regard fecal implants as a drug curing and treating disease instead of being a therapeutic procedure. The resulting effect of the sophisticate procedure to get approval to use feces led to most of the medical practitioner opting for alternative means of treatment in place of feces which had proven to be 90% effective in treating “Clostridium difficile” (Frank et al., 2014). Furthermore, the FDA is yet to ban the application of antibiotics in the factory farm products used to fatten animals faster and reduce the risk of the animals being affected by the health complications resulting from extreme confinement.

According to Kesselheim & Avorn (2016), approximately 2 million people experience health complications as a result of the drug-resistant bacteria present in the animal products. Neglecting the challenges encountered by the FDA will result in the worsening of the health complications and disease attacks on the consumers of manufactured food and drugs in the country. In this case, it is essential that the limitations within the FDA are looked into and solution arrived at for the purpose of protecting and promoting the health of the food and drug consumers around the world.

References
Frank, C., Himmelstein, D. U., Woolhandler, S., Bor, D. H., Wolfe, S. M., Heymann, O., & Lasser, K. E. (2014). The era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Affairs, 33(8), 1453-1459.
Kesselheim, A. S., & Avorn, J. (2016). Approving a problematic muscular dystrophy drug: implications for FDA policy. Jama, 316(22), 2357-2358.
Kim, C., & Prasad, V. (2015). Cancer drugs approved on the basis of a surrogate endpoint and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA internal medicine, 175(12), 1992-1994.